Literature DB >> 17467496

Piperazine designer drugs of abuse.

Roland F Staack1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17467496     DOI： 10.1016/S0140-6736(07)60646-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

2.  Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users.

Authors:  Tibor M Brunt; Maarten W Koeter; Raymond J M Niesink; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2011-10-13       Impact factor: 4.530

3.  Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]).

Authors:  Satnam Lidder; Paul Dargan; Michael Sexton; Jenny Button; John Ramsey; David Holt; David Wood
Journal:  J Med Toxicol       Date:  2008-09

4.  Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP).

Authors:  David M Wood; Jenny Button; Satnam Lidder; John Ramsey; David W Holt; Paul I Dargan
Journal:  J Med Toxicol       Date:  2008-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.